Bibliographic Details
| Title: |
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP. |
| Authors: |
Nemec, Ronald1 (AUTHOR), Scherrer-Crosbie, Marielle2 (AUTHOR), Abramson, Jeremy S.1 (AUTHOR), Redd, Robert3 (AUTHOR), Gilman, Hannah K.4 (AUTHOR), Ho, Terry4 (AUTHOR), Wu, Jessica4 (AUTHOR), Heemelaar, Julius4 (AUTHOR), Neuberg, Donna3 (AUTHOR), Hochberg, Ephraim P.1 (AUTHOR), Barnes, Jeffrey A.1 (AUTHOR), Armand, Philippe5 (AUTHOR), Jacobsen, Eric D.5 (AUTHOR), Jacobson, Caron A.5 (AUTHOR), Kim, Austin I.5 (AUTHOR), Friedman, Robb S.6 (AUTHOR), LaCasce, Ann S.5 (AUTHOR), Neilan, Tomas G.4 (AUTHOR), Soumerai, Jacob D.1 (AUTHOR) jsoumerai@mgb.org |
| Source: |
Leukemia & Lymphoma. Jun2024, Vol. 65 Issue 6, p783-788. 6p. |
| Subject Terms: |
*DIFFUSE large B-cell lymphomas, *ATORVASTATIN, *ANTINEOPLASTIC combined chemotherapy protocols, *PLACEBOS |
| Abstract: |
STOP-CA was a multicenter, double-blind, randomized, placebo-controlled trial comparing atorvastatin to placebo in treatment-naïve lymphoma patients receiving anthracycline-based chemotherapy. We performed a preplanned subgroup to analyze the impact of atorvastatin on efficacy in patients with diffuse large B-cell lymphoma (DLBCL). Patients received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at standard doses for six 21-day cycles and were randomly assigned to receive atorvastatin 40 mg daily (n = 55) or placebo (n = 47) for 12 months. The complete response (CR) rate was numerically higher in the atorvastatin arm (95% [52/55] vs. 85% [40/47], p =.18), but this was not statistically significant. Adverse event rates were similar between the atorvastatin and placebo arms. In summary, atorvastatin did not result in a statistically significant improvement in the CR rate or progression-free survival, but both were numerically improved in the atorvastatin arm. These data warrant further investigation into the potential therapeutic role of atorvastatin added to anthracycline-based chemotherapies. [ABSTRACT FROM AUTHOR] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
